Home Cart Sign in  
Chemical Structure| 96797-15-8 Chemical Structure| 96797-15-8
Chemical Structure| 96797-15-8
Product Citations

Alternative Products

Product Details of [ 96797-15-8 ]

CAS No. :96797-15-8
Formula : C22H17IN2
M.W : 436.29
SMILES Code : C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3)[N]4C=C(N=C4)I
MDL No. :MFCD02179542
Boiling Point : No data available
InChI Key :DXJZJYPLPZEYBH-UHFFFAOYSA-N
Pubchem ID :618252

Safety of [ 96797-15-8 ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Calculated chemistry of [ 96797-15-8 ] Show Less

Physicochemical Properties

Num. heavy atoms 25
Num. arom. heavy atoms 23
Fraction Csp3 0.05
Num. rotatable bonds 4
Num. H-bond acceptors 1.0
Num. H-bond donors 0.0
Molar Refractivity 109.55
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

17.82 Ų

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

3.45
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

5.47
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

5.33
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

4.59
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

5.3
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

4.83

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

-6.41
Solubility 0.000171 mg/ml ; 0.000000391 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Poorly soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

-5.6
Solubility 0.00109 mg/ml ; 0.0000025 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Moderately soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-8.85
Solubility 0.000000621 mg/ml ; 0.0000000014 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Poorly soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

High
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

Yes
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

Yes
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

Yes
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

Yes
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

Yes
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

Yes
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

Yes
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-5.08 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

1.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

0.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

0.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

1.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.55

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

1.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

No; 1 violation:MW<2.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

3.14

Application In Synthesis [ 96797-15-8 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 96797-15-8 ]

[ 96797-15-8 ] Synthesis Path-Downstream   1~5

  • 1
  • [ 96797-15-8 ]
  • [ 68-12-2 ]
  • [ 15469-97-3 ]
  • 4-iodo-2-formyl-1-tritylimidazole [ No CAS ]
  • [ 67478-50-6 ]
  • [ 33016-47-6 ]
  • 2
  • [ 26421-44-3 ]
  • [ 96797-15-8 ]
  • (2,5-dimethylthien-3-yl)-1-trityl-imidazol-4-yl-methanol [ No CAS ]
YieldReaction ConditionsOperation in experiment
With ethylmagnesium bromide; In diethyl ether; dichloromethane; EXAMPLE 5 4-[(2,5-dimethylthien-3-yl)methyl]-1H-imidazole Fumarate STR45 To a solution of N-trityl-4-iodo-imidazole (11.8 g, 27 mmol) in dry CH2 Cl2 (200 mL) was added EtMgBr (11.0 mL, 3.0M in Et2 O). After complete halogen-metal exchange this solution was cannulated into a solution of <strong>[26421-44-3]2,5-dimethylthiophene-3-carboxaldehyde</strong> (3.5 g, 25 mmol) in 50 mL of CH2 Cl2. The reaction mixture was stirred at room temperature for 1 hr and then quenched with aqueous NH4 Cl. The mixture was transferred to a separatory funnel and the aqueous layer was extracted with a second portion of CH2 Cl2. The combined extracts were dried (MgSO4) and filtered. The solvent was evaporated in vacuo to give a thick syrup which was triturated with Et2 O to give a solid which was recrystallized from acetone to give (2,5-dimethylthien-3-yl)-1-trityl-imidazol-4-yl-methanol, A5. 1 H NMR (CDCl3) supported the assigned structure. STR46
  • 3
  • [ 5779-93-1 ]
  • [ 96797-15-8 ]
  • [ 176721-01-0 ]
YieldReaction ConditionsOperation in experiment
84% Example 1 (step a); Preparation of (2,3-Dimethylphenyl)-(3-trityl-3H-imidazol-4-yl)methanol A solution of isopropylmagnesium bromide in tetrahydrofuran (48 mL, 0.046 mol) was added to a stirred solution of 4-iodo-1-trityl-1 H-imidazole (19.0 g, 0.046 mol) in dichloromethane (180 mL) at 10 to 15°C. The reaction mixture was allowed to warm to the ambient temperature and was stirred at ambient temperature for 1 hour. The reaction mixture was then cooled to 10-15°C, at which point a solution of <strong>[5779-93-1]2,3-dimethylbenzaldehyde</strong> (6.2 mL, 0.046 mol) in dichloromethane (10 mL) was added, while not exceeding 20 to 25°C. After additional stirring for 1 hour at ambient temperature a 10percent aqueous ammonium chloride solution (200 mL) was added to the reaction mixture. The organic layer was separated and washed with an aqueous sodium chloride solution (150 mL), thereafter the organic layer was concentrated to a volume of 40 mL. A precipitate of (2,3-dimethylphenyl)-(3-trityl-3H-imidazol-4-yl)methanol was obtained upon cooling the distillation residue to 4°C and it was separated by filtration, then washed with dichloromethane (50 mL). The intermediate (2,3-dimethylphenyl)-(3-trityl-3H-imidazol-4-yl)methanol was dried at ambient temperature. The yield was 17.4 g (84 percent) of a white or off-white powder, having a melting temperature of 203.0 to 207.0°C.
  • 4
  • [ 38696-20-7 ]
  • [ 96797-15-8 ]
  • [ 1217902-45-8 ]
YieldReaction ConditionsOperation in experiment
65% To a solution of 4-Iodo-1-trityl-1H-imidazole (Synthonix, 2.0 g, 4.58 mmol) in THF (50 mL) at room temperature was added ethylmagnesium bromide (Aldrich, 1.0 M solution in THF, 5.5 mL, 5.50 mmol) under dry conditions. After stirring for 90 minutes, zinc chloride (Aldrich, 0.749. g, 5.50 mmol) was added to the reaction mixture. After stirring for an additional 90 minutes, tetrakis(triphenyl)phosphine)palladium (Strem, 0.529 g, 0.46 mmol) and <strong>[38696-20-7]5-bromo-2-phenylpyrimidine</strong> (as prepared in Example 1, step A, 1.29 g, 5.50 mmol) were added to the reaction mixture. The reaction mixture was heated in a 70° C. oil bath overnight. Upon cooling, the reaction was diluted with dichloromethane and washed with 0.5 M EDTA buffer (at pH ~9) (2*250 mL) followed by brine (150 mL). The organics were dried over sodium sulfate, filtered, and concentrated. The crude product was purified by flash silica column chromatography using an 80 g Silicycle.(R). column (elution with 10-30percent ethyl acetate in hexane) which afforded the desired intermediate, 2-phenyl-5-(1-trityl-1H-imidazol-4-yl)pyrimidine, as a white solid (1.38 g, 65percent). Rf 0.87 with 95:5 v/v dichloromethane-methanol; 1H-NMR (400 MHz; DMSO-d6) delta 9.29 (s, 2H), 8.42 (m, 2H), 7.92 (d, 1H), 7.62 (d, 1H), 7.56-7.43 (m, 13H), 7.24-7.22 (m, 6H); MS (ESI-) m/z 463.0 (M-1); H-PGDS FPBA IC50: >20 muM.
  • 5
  • [ 1252858-34-6 ]
  • [ 96797-15-8 ]
  • C51H72N6O4Si3 [ No CAS ]
  • [ 15469-97-3 ]
 

Historical Records

Technical Information

Categories

Related Functional Groups of
[ 96797-15-8 ]

Aryls

Chemical Structure| 15469-97-3

A181599 [15469-97-3]

1-Trityl-1H-imidazole

Similarity: 0.85

Chemical Structure| 33016-47-6

A125745 [33016-47-6]

1-Trityl-1H-imidazole-4-carbaldehyde

Similarity: 0.73

Chemical Structure| 78430-91-8

A261711 [78430-91-8]

1-(4-Vinylbenzyl)-1H-imidazole

Similarity: 0.69

Chemical Structure| 4238-71-5

A135013 [4238-71-5]

1-Benzyl-1H-imidazole

Similarity: 0.67

Chemical Structure| 56643-85-7

A176992 [56643-85-7]

4-Imidazol-1-ylmethylphenylamine

Similarity: 0.63

Related Parent Nucleus of
[ 96797-15-8 ]

Imidazoles

Chemical Structure| 15469-97-3

A181599 [15469-97-3]

1-Trityl-1H-imidazole

Similarity: 0.85

Chemical Structure| 33016-47-6

A125745 [33016-47-6]

1-Trityl-1H-imidazole-4-carbaldehyde

Similarity: 0.73

Chemical Structure| 78430-91-8

A261711 [78430-91-8]

1-(4-Vinylbenzyl)-1H-imidazole

Similarity: 0.69

Chemical Structure| 4238-71-5

A135013 [4238-71-5]

1-Benzyl-1H-imidazole

Similarity: 0.67

Chemical Structure| 56643-85-7

A176992 [56643-85-7]

4-Imidazol-1-ylmethylphenylamine

Similarity: 0.63